


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on October 31, 2007.


Frank C. Eisenschenk, Ph.D., Patent Attorney

RESPONSE UNDER 37 C.F.R. § 1.114
Examining Group 1617
Patent Application
Docket No. MET-037CXT
Serial No. 09/900,364

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Leonard M. Williams
Art Unit : 1617
Applicants : Paul D. van Poelje, Mark D. Erion, Toshihiko Fujiwara
Serial No. : 09/900,364
Filed : July 5, 2001
Conf. No. : 7049
For : Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

RESPONSE UNDER 37 C.F.R. § 1.114

Sir:

The remarks that follow are submitted for the Examiner's consideration in the above-referenced patent application in response to the Office Action dated October 22, 2007.